Founded in 1994, Euroscreen SA is a clinical-stage, privately-held biotechnology company based in Belgium. Our mission is to invent and develop small-molecule drug candidates to valuable endpoints for licensing/partnering with pharmaceutical companies. Euroscreen's competitive advantage comes from our focus on GPCRs drug targets and the proven efficiency of our integrated research team to deliver innovative drug candidates through to preclinical or early clinical endpoints attractive to big pharma partners.
Location: Belgium
Employees: 11-50
Founded date: 1994
Investors 2
| Date | Name | Website |
| - | Theodorus | theodorus.... |
| - | Capricorn ... | capricorn.... |
Mentions in press and media 5
| Date | Title | Description |
| 03.04.2017 | Term Sheet — Monday, April 3 | BIG DEAL Hello. Just about every beat at Fortune is enjoying some deal-making action at the moment, so this morning’s Term Sheet is a team effort… Paid Content Securing the enterprise without boundaries From ExtraHop • Why hasn’t VF landed ... |
| 03.04.2017 | Astellas swoops in on a mid-stage drug for hot flashes in $860M biotech buyout deal | Astellas Pharma’s Illinois campus Three months after the Belgian biotech Ogeda reported solidly positive data from a Phase IIa study of its experimental, non-hormonal therapy for hot flashes related to menopause, the... |
| 02.04.2017 | Astellas to acquire Ogeda SA | Tokyo, Japan, and Gosselies, Belgium: 2 April 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) and Ogeda SA (CEOFJean Combalbert) announced today that Astellas and Ogeda shareholders have entered into a defini... |
| 02.04.2017 | Astellas to acquire Ogeda SA Copy | Tokyo, Japan, and Gosselies, Belgium: 2 April 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) and Ogeda SA (CEOFJean Combalbert) announced today that Astellas and Ogeda shareholders have entered into a defini... |
| 20.12.2016 | Ogeda announces fezolinetant as INN and issuance of US patent for ESN364 | Gosselies, Belgium: 20 December 2016 – Ogeda, a clinical-stage drug discovery company that invents and develops small molecule drug candidates targeting G-protein coupled receptors (GPCRs), announces today that the World Health Organization... |